Related references
Note: Only part of the references are listed.A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies
Christina W. Guo et al.
EUROPEAN JOURNAL OF CANCER (2020)
Cancer patients receiving immune checkpoint inhibitor therapy are at an increased risk for atherosclerotic cardiovascular disease
Esther Lutgens et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Cardiac biomarkers for the detection of cardiotoxicity in childhood cancer-a meta-analysis
Lars Michel et al.
ESC HEART FAILURE (2020)
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
T.K. Choueiri et al.
ANNALS OF ONCOLOGY (2020)
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
Vicky Makker et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from theCardio-Oncology Study Groupof theHeart Failure Associationand theCardio-Oncology Council of the European Society of Cardiology
Radek Pudil et al.
EUROPEAN JOURNAL OF HEART FAILURE (2020)
Cardiovascular toxicities associated with immune checkpoint inhibitors
Jiun-Ruey Hu et al.
CARDIOVASCULAR RESEARCH (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience
Katherine Lee Chuy et al.
ONCOLOGIST (2019)
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Brian I. Rini et al.
LANCET (2019)
Myocarditis in the Setting of Cancer Therapeutics Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology
Marc P. Bonaca et al.
CIRCULATION (2019)
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Syed S. Mahmood et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events
Rhian M. Touyz et al.
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2018)
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
Javid J. Moslehi et al.
LANCET (2018)
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study
Joe-Elie Salem et al.
LANCET ONCOLOGY (2018)
The Role of Biomarkers in Detection of Cardio-toxicity
Kevin S. Shah et al.
CURRENT ONCOLOGY REPORTS (2017)
Cardiovascular Toxicities Associated with Cancer Immunotherapies
Daniel Y. Wang et al.
CURRENT CARDIOLOGY REPORTS (2017)
Cardiovascular risk stratification in hemodialysis patients in the era of highly sensitive troponins: should we choose between hs-troponin I and hs-troponin T?
Anne-Sophie Bargnoux et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2016)
Cardiovascular Toxic Effects of Targeted Cancer Therapies
Javid J. Moslehi
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805
Naomi B. Haas et al.
CLINICAL CANCER RESEARCH (2015)
Direct comparison of high-sensitivity-cardiac troponin I vs. T for the early diagnosis of acute myocardial infarction
Maria Rubini Gimenez et al.
EUROPEAN HEART JOURNAL (2014)
Cardiovascular complications associated with novel angiogenesis inhibitors: Emerging evidence and evolving perspectives
Steven M. Bair et al.
TRENDS IN CARDIOVASCULAR MEDICINE (2013)
Predictors of high sensitivity cardiac troponin T in chronic kidney disease patients: a cross-sectional study in the chronic renal insufficiency cohort (CRIC)
Ruth F. Dubin et al.
BMC NEPHROLOGY (2013)
Analytical Characteristics of High-Sensitivity Cardiac Troponin Assays
Fred S. Apple et al.
CLINICAL CHEMISTRY (2012)
Serum troponins as biomarkers of drug-induced cardiac toxicity
KB Wallace et al.
TOXICOLOGIC PATHOLOGY (2004)